Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2023/07/054894
CTRI/2023/07/054894
Not yet recruiting
Phase 3

Evaluation of efficacy of Hydroxychloroquine as an add-on therapy to antithyroid drugs in the treatment of Graves disease: A Pilot study - Not Applicable

IPQA laboratories0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: E050- Thyrotoxicosis with diffuse goiter

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: E050- Thyrotoxicosis with diffuse goiter
Sponsor
IPQA laboratories
Status
Not yet recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
IPQA laboratories

Eligibility Criteria

Inclusion Criteria

  • •Patients with newly diagnosed Graveâ??s disease with serum total T4 levels more than 20 microgram/dl.

Exclusion Criteria

  • •1\. Pregnant and lactating women
  • •2\. Patients on corticosteroids or immunosuppressive drugs
  • •3\. Patients in whom the use of hydroxychloroquine is contraindicated.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic HIV-infected patients (HCQ-01) - Hydroxychloroquine studyHIV infectionMedDRA version: 9.1Level: LLTClassification code 10020161Term: HIV infection
EUCTR2007-005057-36-GBMedical Research Council
Completed
Not Applicable
HCQ-01 Trial: evaluation of the efficacy of hydroxychloroquine in decreasing immune activation in asymptomatic human immunodeficiency virus (HIV) infected patients
ISRCTN30019040Medical Research Council Clinical Trials Unit (MRC CTU) (UK)90
Recruiting
Not Applicable
Evaluate the efficacy of hydroxychloroquine in the prevention of SARS-COV2 infection in high risk health care workers
IRCT20200414047076N1Esfahan University of Medical Sciences160
Recruiting
Phase 3
Hydroxychloroquine in comparison with hydroxychloroquine + azithromycin in patients with covid-19COVID-19.U07.1 - COVID-19COVID-19
IRCT20200428047228N2Quality Improvement of Intensive Care Research Center- Shahid Beheshti University40
Active, not recruiting
Not Applicable
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922
EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40